Division of Luminex Corp.
Latest From Nanosphere Inc.
US FDA released five device-related close-out letters in June.
No significant trends emerged in diagnostics M&A or financing this past year, which did see the introduction of several government-funded initiatives, elements of which will bolster diagnostics innovation. As in other sectors of health care, the biggest question is how the incoming Trump administration could change US regulatory and funding policies.
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Recent regulatory events and dealmaking highlight an increase in the pace of innovation in rapid infectious disease testing.
- Nanotechnology, Chips, etc.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Infectious & Viral Diseases
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- Luminex Corp.
- Senior Management
Michael P McGarrity, Pres. & CEO
J. Roger, Jr. Moody, CFO
- Contact Info
Phone: (847) 400-9000
4088 Commercial Ave.
Northbrook, IL 60062
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.